Proteolytic processing, deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome coronavirus papain-like protease
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The emerging Middle East respiratory syndrome coronavirus (MERS-CoV) causes severe pulmonary disease in humans and represents the second example of a highly pathogenic coronavirus (CoV) following severe acute respiratory syndrome coronavirus (SARS-CoV). Genomic studies revealed that two viral proteases, papain-like protease (PLpro) and 3C-like protease (3CLpro), process the polyproteins encoded by the MERS-CoV genomic RNA. We previously reported that SARS-CoV PLpro acts as both deubiquitinase (DUB) and IFN antagonist, but the function of the MERS-CoV PLpro was poorly understood. In this study, we characterized MERS-CoV PLpro, which is a protease and can recognize and process the cleavage sites (CS) of nsp1-2, nsp2-3 and nsp3-4. The LXGG consensus cleavage sites in the N terminus of pp1a/1ab, which is generally essential for CoV PLpro-mediated processing, were also characterized in MERS-CoV. MERS-CoV PLpro, like human SARS-CoV PLpro and NL63-CoV PLP2, is a viral deubiquitinating enzyme. It acts on both K48- and K63-linked ubiquitination and ISG15-linked ISGylation. We confirmed that MERS-CoV PLpro acts as an IFN antagonist through blocking the phosphorylation and nuclear translocation of IFN regulatory factor 3 (IRF3). These findings indicate that MERS-CoV PLpro acts as a viral DUB and suppresses production of IFN-β by an interfering IRF3-mediated signalling pathway, in addition to recognizing and processing the CS at the N terminus of replicase polyprotein to release the non-structural proteins. The characterization of proteolytic processing, DUB and IFN antagonist activities of MERS-CoV PLpro would reveal the interactions between MERS-CoV and its host, and be applicable to develop strategies targeting PLpro for the effective control of MERS-CoV infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation and cellular roles of ubiquitin-specific deubiquitinating enzymes.
Reyes-Turcu, F. E., Ventii, K. H., & Wilkinson, K. D. (2009) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.78.082307.091526 · Cited by 1,396 · cited 1×
“Cellular DUBs alter the fate of proteins in specific signalling pathways of the cell (Katz et al., 2010; Reyes-Turcu et al., 2009), for example deubiquitination may protect the ubiquitinated proteins from degradation, and affect the proteins which are modified by Ub-like proteins, such as ISGs (van der Veen & Ploegh,…”
BackgroundHospital outbreak of Middle East respiratory syndrome coronavirus
Assiri, A., McGeer, A., Perl, T. M., Price, C. S., Al Rabeeah, A. A., Cummings, D. A. T., Alabdullatif, Z. N., Assad, M., Almulhim, A., Makhdoom, H., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306742 · Cited by 1,196
Devaraj, S. G., Wang, N., Chen, Z., Chen, Z., Tseng, M., Barretto, N., Lin, R., Peters, C. J., Tseng, C.-T. K., Baker, S. C., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704870200 · Cited by 411 · cited 10×
“6a, the IFN-b promoter was activated 100-fold when the cells were transfected with RIG-IN, whereas the IFN-b promoter activated by RIG-IN was completely inhibited in the presence of MERS-CoV PLpro-TM, which was similar to the previously reported IFN antagonist activity of SARSCoV PLpro and NL63-CoV PLP2 (Clementz et a…”
BackgroundMethodResultInfluentialSelf-citationVaux, D. L., Fidler, F., & Cumming, G. (2012) · The EMBO Reports · doi:10.1038/embor.2012.36 · Cited by 155 · cited 1×
“05 was considered statistically significant (Kiefer et al., 2009; Vaux et al., 2012).”
Cited by
Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity
Volz, E., Hill, V., McCrone, J. T., Price, A., Jorgensen, D., O’Toole, Á., Southgate, J., Johnson, R., Jackson, B., Nascimento, F. F., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.020 · Cited by 1,006
Chan, J. F. W., Lau, S. K. P., To, K. K. W., Cheng, V. C. C., Woo, P. C. Y., & Yuen, K.-Y. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-14 · Cited by 881
Nsp3 of coronaviruses: Structures and functions of a large multi-domain protein
Lei, J., Kusov, Y., & Hilgenfeld, R. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2017.11.001 · Cited by 727
Human Coronaviruses: A Review of Virus–Host Interactions
Lim, Y., Ng, Y., Tam, J., & Liu, D. (2016) · Diseases · doi:10.3390/diseases4030026 · Cited by 591
Chu, H., Zhou, J., Wong, B. H.-Y., Li, C., Chan, J. F.-W., Cheng, Z.-S., Yang, D., Wang, D., Lee, A. C.-Y., Li, C., et al. (2016) · Journal of Infectious Diseases · doi:10.1093/infdis/jiv380 · Cited by 448
COVID-19: Drug Targets and Potential Treatments
Gil, C., Ginex, T., Maestro, I., Nozal, V., Barrado-Gil, L., Cuesta-Geijo, M. Á., Urquiza, J., Ramírez, D., Alonso, C., Campillo, N. E., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00606 · Cited by 445
COVID-19 vaccines: The status and perspectives in delivery points of view
Chung, J. Y., Thone, M. N., & Kwon, Y. J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.011 · Cited by 375
MERS-CoV spike protein: a key target for antivirals
Du, L., Yang, Y., Zhou, Y., Lu, L., Li, F., & Jiang, S. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1271415 · Cited by 301
Moustaqil, M., Ollivier, E., Chiu, H.-P., Van Tol, S., Rudolffi-Soto, P., Stevens, C., Bhumkar, A., Hunter, D. J. B., Freiberg, A. N., Jacques, D., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2020.1870414 · Cited by 283
Oudshoorn, D., Rijs, K., Limpens, R. W. A. L., Groen, K., Koster, A. J., Snijder, E. J., Kikkert, M., & Bárcena, M. (2017) · mBio · doi:10.1128/mbio.01658-17 · Cited by 245
Chen, X., Wang, K., Xing, Y., Tu, J., Yang, X., Zhao, Q., Li, K., & Chen, Z. (2014) · Protein & Cell · doi:10.1007/s13238-014-0104-6 · Cited by 130
Self-citationAhmed-Hassan, H., Sisson, B., Shukla, R. K., Wijewantha, Y., Funderburg, N. T., Li, Z., Hayes, D., Demberg, T., & Liyanage, N. P. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01979 · Cited by 47
Metadata
- Authors
- Yang, X., Chen, X., Bian, G., Tu, J., Xing, Y., Wang, Y., & Chen, Z.
- Venue
- Journal of General Virology
- Publisher
- Microbiology Society
- Published
- 2014-03-01
- Volume
- 95
- Issue
- 3
- Pages
- 614-626
- ISSN
- 0022-1317 (ISSN-L)
- 1465-2099
- OpenAlex
- W2026229430
- Cited by
- 154
- References
- 4
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.